S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
With docetaxel after doxorubicin plus cyclophosphamide as a neoadjuvant therapy in breast cancer: Phase II trial